The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) ...
GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group.
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal ...
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...
In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...
Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...
Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...
Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...
Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...
Pfizer is doubling down on its commitment to China as the company continues to face activist pressure around its plans for a ...
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback